

Translating the Intention to Seek Treatment into Action: Does Symptom Monitoring Make a Difference? Results from a Randomized Controlled Trial

R. Shafran

UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK

A. Gyani*

School of Psychology and Clinical Language Sciences, University of Reading, Reading, Berkshire RG6 6AL, UK

J. Rostron

School of Systems Engineering, University of Reading, Reading, Berkshire RG6 6AY, UK

S. Allen

Department of Politics & International Relations, University of Reading, Reading, Berkshire RG6 6AA, UK

P. Myles-Hooton

School of Psychology and Clinical Language Sciences, University of Reading, Reading, Berkshire RG6 6AL, UK

H. Allcott-Watson

UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK

S. Rose

Berkshire Healthcare NHS Foundation Trust, 2nd, 3rd and 4th Floors Fitzwilliam House, Bracknell, Berkshire RG12 1BQ, UK

Correspondence to Alex Gyani, Behavioural Insights Team (Australia), Level 13, 167 Macquarie Street, Sydney, NSW 2000, Australia. E-mail: alex.gyani@bi.team

* Alex Gyani is now Principal Advisor (APAC ~~Research & Evaluation Lead~~) at the Behavioural Insights Team (Australia).

Background: Most people with common mental health problems do not seek evidence-based psychological interventions. **Aims:** The aim of this study was to investigate whether monitoring symptoms of depression and anxiety using an app increased treatment-seeking. **Method:** Three hundred and six people with significant levels of anxiety and depression, none of whom were currently receiving treatment, were randomly allocated to receive either (a) information about local psychological services only, (b) information plus regular symptom monitoring (every 6 days), or (c) information plus open symptom monitoring (monitoring when they felt like it). An app was used to provide information and monitor mood. **Results:** The proportion of participants who reported receiving treatment after starting the study was 7.2% (10/138) in the information only group, 8.1% (9/111) in the information plus regular monitoring group and 15.8% (9/57) in the information plus open monitoring group. There was a trend for participants who were able to monitor whenever they wished to be more likely to report receiving treatment than people who were only given information about their local treatment services. The impact of the intervention was greatest among participants who intended to seek treatment before taking part. Limitations were that only a small minority of those who downloaded the app completed the study and that the study relied on self-reported measures of treatment-seeking. **Conclusions:** Symptom monitoring can increase actual treatment-seeking in those with an intention to seek treatment.

Keywords: treatment seeking, anxiety, depression, eMental Health, monitoring

Introduction

Epidemiological studies have found that one in six people in England suffer from anxiety and/or depressive disorders at any point in time (McManus et al., 2009) and these debilitating disorders are undertreated (Kessler and Ustun, 2008; Wang et al., 2005). The Adult Psychiatric Morbidity Survey in England indicated that only 10% of people with such common mental health problems receive psychological interventions (McManus et al., 2009). When psychological therapy is received, it is often after long delays, is frequently suboptimal and is not evidence-based (Shafran et al., 2009; Wang et al., 2005, 2007). This is despite the fact that people presenting with common mental health disorders prefer psychological treatments to medication (Kwan et al., 2010; McHugh et al., 2013) and prefer psychological treatments that have more empirical support than those that do not (Tarrier et al., 2006).

One reason why common mental health problems are undertreated is that people often do not seek help (McManus et al., 2009). A number of interventions to increase treatment receipt and encourage people to seek treatment for common mental health disorders have been designed. A systematic review (Gulliver et al., 2012) evaluated these interventions in relation to help-seeking intent and help-seeking behaviour. The interventions in the review included (1) giving people information to increase mental health literacy, (2) giving people information about where to seek treatment, (3) giving people destigmatizing information and (4) giving people computerized cognitive behavioural therapy (CBT) with personalized feedback about the individual's symptoms. The review concluded that these interventions had a positive impact on intention to seek treatment but little effect on actual treatment seeking, with the exception of the computerized CBT intervention (Christensen et al., 2006), which could arguably be considered treatment in and of itself.

Intention to seek treatment is a potential predictor of treatment receipt (Gulliver et al., 2010, 2012; Schomerus et al., 2009). It is therefore possible that those with high intention to seek treatment would benefit from a relatively minor intervention that, according to theoretical

67 models, tips the balance for them to translate intention into action (Ajzen, 1991; Prochaska
68 and DiClemente, 1982).

69 One potential method to encourage patients to seek treatment is for them to monitor their
70 symptoms of anxiety and/or depression, receive feedback about the severity of their symptoms
71 and to obtain information on the availability of treatment. Such monitoring of symptoms is
72 increasingly common on the internet with a number of freely available applications (NHS
73 Choices Reporting Team, 2012).

74 Weekly symptom monitoring is effective in improving treatment outcomes when it is
75 administered either before or after a treatment session (Kordy et al., 2001; Lambert et al.,
76 2003; Lutz et al., 2006). A study by Drake and colleagues investigated the impact of completing
77 an online symptom monitoring tool (called Moodscope) daily in people currently receiving
78 treatment (Drake et al., 2012). The majority of participants found that the symptom monitoring
79 tool helped them manage their symptoms. When interviewed, some participants suggested that
80 symptom monitoring might benefit other people experiencing these disorders who were not
81 yet willing to see a clinician. However, as of yet the impact of symptom monitoring on seeking
82 or receiving treatment is not known.

83 The primary aim of this study was to evaluate whether monitoring symptoms of anxiety
84 and/or depression increased reported actual receipt of treatment. An application was created
85 for Apple iOS devices (iPhone and iPad), called 'Mood Mate'. A cell phone is an ideal
86 medium for monitoring symptoms as it is easily accessible 24 hours a day, and application
87 allowed participants to monitor their symptoms of anxiety and depression. As this study is
88 the first of its kind, the optimal frequency of monitoring to encourage treatment receipt was
89 unknown and it was decided to allocate people to monitoring symptoms every 6 days or open
90 monitoring, i.e. whenever the participant chose to. Six-day monitoring was selected because
91 psychological treatment sessions are often conducted weekly. As a given day of the week may
92 be a confounding factor, it was decided that every 6 days would be optimal. Limiting the use of
93 the tool to every 6 days contrasts with tools like Moodscope, which can be completed whenever
94 the participant wishes and might be beneficial. To increase ecological validity, participants in
95 the open monitoring group were able to monitor whenever they liked.

96 Participants were randomized into three groups that were given: (a) information about local
97 psychological services only, (b) information plus regular symptom monitoring (every 6 days)
98 and (c) information plus open symptom monitoring (monitoring when they chose to). After 30
99 days, participants were asked whether they had received treatment since starting the study.

100 It was predicted that among people with significant levels of anxiety and depression: (1)
101 participants who monitored their symptoms would be more likely to report receiving treatment
102 over a 30-day period than participants who only received information about local treatments,
103 and (2) monitoring symptoms would have a significant impact on treatment receipt in those
104 that already intended to seek treatment. No specific hypothesis was made regarding differences
105 between the 6-day and open monitoring groups as this was the first study of its kind.

106

Method

107

Recruitment

108

The application (app) was made available on the iTunes App Store and was on the front page
109 for the first week of its release. We used social and traditional media methods of encouraging

110 people to download the app. This included a Twitter Feed, radio interviews and a press release.
111 Advertisements focused on the monitoring of mood.

112 *Participants*

113 To be eligible to participate in the study participants were required to (1) have an iOS device
114 to run the Mood Mate application, (2) be 18 years or older, (3) be based in England, (4) be
115 reasonably proficient to read and understand the language of instruction which was English,
116 and (5) score above threshold on either the PHQ-4 (Patient Health Questionnaire-4), a four-item
117 measure of depression, or the Mini SPIN (Mini Social Phobia Inventory), a three-item screen
118 for social anxiety disorder. The thresholds were set at 3 on either the anxiety or depression
119 components of the PHQ-4 and 3 on the Mini SPIN, indicating that they were likely to have an
120 anxiety or mood disorder (Kroenke et al., 2009; Weeks et al., 2007).

121 Participants who met the inclusion criteria on the screening and stated that they were already
122 receiving treatment at the time of the study were included in the study but excluded from the
123 analysis ($n = 1952$, 22.5%). The mean age of the 306 participants who remained in the analysis
124 was 27.2 years old ($SD = 9.7$). The majority of participants were female ($n = 217$, 70.9%)
125 and a large proportion of the sample had never received treatment ($n = 228$, 74.5%). The
126 majority of participants were Caucasian ($n = 256$, 83.7%), 9.5% ($n = 29$) were Asian, 2.3%
127 ($n = 7$) were Mixed Race, 2.3% ($n = 7$) were Black and 2.3% ($n = 7$) of participants stated that
128 they were of an 'other' ethnicity, or did not wish to divulge their ethnicity. Sixty-two (20.3%)
129 participants did not meet the threshold on the PHQ-4, but did score above the threshold on the
130 Mini SPIN.

131 *Procedure*

132 Once participants downloaded the app they were shown information about the study and were
133 screened with the Patient Health Questionnaire-4 (PHQ-4) which consists of the first two items
134 of the PHQ-9 (referred to as the PHQ-2) and the first two items of the GAD-7 (see below).
135 If potential participants scored below the threshold on the PHQ-4, which does not screen
136 avoidance behaviours, they were asked to complete the Mini Social Phobia Inventory (Mini
137 SPIN) to detect social anxiety. If participants scored below the threshold on both measures
138 they were signposted to a helpline where they could receive support if they wanted it and they
139 did not continue with the study.

140 Those participants who scored above the threshold on either screening measure were
141 presented with a consent form. Participants who consented were then given the baseline
142 questionnaire to establish their baseline characteristics. They were then automatically
143 randomized by the application using a built-in random number generator into either the control
144 group or one of two monitoring groups. Participants in the control group received information
145 about common mental health conditions and possible treatments. They were informed of the
146 location and contact details of all Improving Access to Psychological Therapy (IAPT) services
147 in England including their websites. These are psychological treatment services for anxiety
148 and depression, the majority of which accept self-referrals. The location of the closest IAPT
149 service to the participant could be found using the global positioning system (GPS) location
150 of their iPhone.

151 Participants in the monitoring groups received the same information as the control group.
152 Additionally they were asked to monitor their anxiety and depression symptoms by completing
153 the Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001) and the Generalized Anxiety
154 Disorder Assessment (GAD-7; Spitzer et al., 2006). Those in the 6-day monitoring group were
155 asked to monitor their symptoms every 6 days, while those in the open monitoring group were
156 able to monitor their symptoms as often as they wished. Both groups were sent reminders to
157 monitor their symptoms every 6 days to ensure that all participants received the same number
158 of reminders.

159 Participants in the monitoring groups could view their scores on the PHQ-9 and GAD-7
160 measures graphically over time whenever they accessed the app. Participants were informed
161 of the clinical thresholds for both measures, so they could understand where their symptoms
162 placed them with respect to mild, moderate, moderately severe and severe depression on the
163 PHQ-9 and mild, moderate and severe anxiety on the GAD-7.

164 All participants were asked to not delete the app before completing the post-intervention
165 measure, which was administered after 30 days of app use. After completing the post-
166 intervention measure, participants in the control group were offered the opportunity to use
167 the application's symptom monitoring tools that had been accessible to participants in the
168 experimental groups. All communication with participants was via the app only. In nine cases
169 participants emailed the authors to state that the contact details of IAPT sites were not correct.
170 These were corrected within 48 hours.

171 *Measures and materials*

172 *Mood Mate.* The app was developed by J.R., A.G. and S.A. and was free for participants
173 to download onto iPhones. This app was purely developed as a research tool and had no
174 commercial interest. An earlier prototype of the application was shown to focus groups
175 consisting of service users in the local area, to ensure that it met the needs of potential
176 participants. The app was available to download on the UK iTunes store from 10 October
177 2012 until 9 April 2013 and was promoted via blogs, radio and Twitter.

178 *The Patient Health Questionnaire-4* (PHQ-4; Löwe et al., 2010). The PHQ-4 consists of
179 the first two items of the PHQ-9 (referred to as the PHQ-2) and the first two items of the
180 GAD-7 (referred to as the GAD-2). It is a screening tool for low mood and anxiety, rather
181 than a validated diagnostic tool. The PHQ-4 has been studied in the general population and in
182 Primary Care, with high scores on the measure being found to be associated with functional
183 impairment, disability days, and healthcare use (Kroenke et al., 2009; Löwe et al., 2010). The
184 threshold used in this study was a score of 3 or above on the PHQ-2 and/or the GAD-2, so all
185 participants were likely to have at least mild anxiety and/or depression. Scores range from 0
186 to 12 and are categorized as normal (0–2), mild (3–5), moderate (6–8) and severe (9–12).

187 *The Mini Social Phobia Inventory* (Mini SPIN; Connor et al., 2001). The Mini SPIN is a
188 reliable and valid three-item instrument for screening social anxiety disorder in adults (Seeley-
189 Wait et al., 2009; Weeks et al., 2007). To be included in the study, participants had to score 3
190 or above, as a liberal screening tool for social phobia. Scores range from 0 to 12 and are not
191 categorized into severity groups.

192 *The Patient Health Questionnaire-9* (PHQ-9; Kroenke et al., 2001). The PHQ-9 is a self-
193 administered nine-item questionnaire developed to measure low mood. The PHQ-9 has a
194 sensitivity of 88% and a specificity of 88% for major depression (Kroenke et al., 2001). Scores
195 range from 0 to 27 and are categorized into: healthy (0–5), mild (5–9), moderate (10–14),
196 moderately severe (15–19) and severe (20–27).

197 *The Generalized Anxiety Disorder Assessment* (GAD-7; Spitzer et al., 2006). The GAD-7
198 is a self-administered seven-item questionnaire developed to screen for GAD. It has also been
199 shown as a valid measure of anxious symptomatology across all anxiety disorders using a
200 cut-off of 8 or greater (sensitivity 77%, specificity 82%) (Kroenke et al., 2007). Scores range
201 from 0 to 21 and are categorized into: healthy (0–4), mild (5–9), moderate (10–14) and severe
202 (15–21).

203 *Baseline measure.* Participants were asked eight questions which assessed: gender (binary
204 choice), birth year, ethnicity (applying the 16 categories used by the Office of National
205 Statistics), whether they had ever sought treatment for, and whether they had ever received
206 treatment for, a mental health condition (binary choices). Current treatment-seeking intention
207 for a mental health issue, how effective they believed psychological therapies were in
208 treating common mental health disorders and how effective they believed medication was
209 in treating common mental health disorders were assessed using a 0–100 point analogue scale,
210 administered with sliders.

211 *Post-measure.* The outcome measure was designed to determine whether or not a
212 participant had sought and/or received any treatment for a mental health condition since
213 starting the study (binary choice). If participants indicated that they had received mental
214 health treatment since starting the study, they were asked what their diagnosis was (if they
215 were given one), what treatment they received and from whom they received treatment. These
216 three items were assessed using multiple-choice questions with the possibility to respond
217 in an open text box. Participants were also asked to re-asses how effective they believed
218 psychological therapies were in treating common mental health disorders and how effective
219 they believed medication was in treating common mental health disorders, assessed with 0–100
220 point analogue scale, administered with sliders.

221 *Data analysis plan*

222 To assess whether there were any differences between participants who completed the outcome
223 measures and those who did not, a logistic regression was used. Participants were compared
224 on the basis of their PHQ-4 severity, gender, age, ethnicity, previous receipt of treatment, prior
225 intention to seek treatment and belief in the effectiveness of psychological and pharmacological
226 treatments.

227 To assess whether there were any differences between the three groups, the characteristics
228 of the participants were compared using Kruskal–Wallis tests for continuous variables (PHQ-4
229 severity, age, prior intention to seek treatment, belief in the effectiveness of psychological
230 and pharmacological treatments) and Chi-squared analyses for categorical variables (gender,
231 ethnicity, previous receipt of treatment). As eight tests were performed, a Bonferroni correction
232 was used to adjust *p* values.




Figure 1. CONSORT diagram showing participant flow in the Mood Mate study

233 The primary outcome measure was reported receipt of treatment in the 30 days since starting
 234 the study. Two dummy variables coding participants' groups were used, with the information-
 235 only group acting as the reference group. Lemeshow and Hosmer's goodness of fit test was
 236 used to assess the fit of the models, and all models were shown to fit the data well ($p > .05$)
 237 (Lemeshow and Hosmer, 1982). Effect sizes are expressed as odds ratios (OR) and confidence
 238 intervals are reported. All analyses were conducted using SPSS v19.

239 *Power analyses*

240 Power analyses were conducted using G*Power 3.1 (Faul et al., 2007). A sample of 160 was
 241 needed to find a medium effect when comparing either of the monitoring groups with the
 242 control group, assuming equally balanced groups.

243

Results

244 [Figure 1](#) shows the flow of participants through the study. Participants who were receiving
 245 treatment at the start of the study were excluded from the analysis which is why 8997 met the
 246 clinical threshold and were therefore given access to the tool, but only 6725 were included
 247 in the analysis. Furthermore, given the vast number of participants randomized but the small
 248 number of post-measures completed, it was decided that a completer analysis, rather than an
 249 intent-to-treat analysis, would be performed. Of the 8997 people that were randomized, 306
 250 participants completed the post-measure.

Table 1. Baseline descriptive statistics of the participants in the three conditions and results of the comparisons between the groups

Variable	Control group (<i>n</i> = 138)		6-day monitoring group (<i>n</i> = 111)		Open monitoring group (<i>n</i> = 57)		χ^2 (d.f.)	Adjusted <i>p</i> value
PHQ-4 score (<i>SD</i>)	6.34	(2.68)	6.37	(2.76)	6.09	(2.85)	0.53 (2)	1
Age (<i>SD</i>)	26.57	(9.61)	27.85	(9.81)	27.23	(9.72)	1.01 (2)	1
Female <i>n</i> (%)	94	(68.12%)	84	(75.68%)	110	(68.42%)	1.92 (2)	1
Ethnicity <i>n</i> (%)							8.23 (8)	1
White	113	(81.88%)	98	(88.29%)	45	(78.95%)		
Mixed	3	(2.17%)	1	(0.90%)	3	(5.26%)		
Asian	16	(11.6%)	8	(7.21%)	5	(8.77%)		
Black	3	(2.17%)	3	(2.70%)	1	(1.75%)		
Other or unknown	3	(2.17%)	1	(0.90%)	3	(5.26%)		
Intention to seek treatment (<i>SD</i>)	29.07	(29.17)	34.52	(33.67)	30.70	(31.00)	0.91 (2)	1
Belief in the effectiveness of psychotherapy (<i>SD</i>)	57.58	(24.05)	54.24	(29.63)	49.86	(28.22)	2.61 (2)	1
Belief in the effectiveness of medication (<i>SD</i>)	44.38	(25.87)	41.68	(29.98)	38.81	(25.61)	1.79 (2)	1
Received treatment before <i>n</i> (%)	28	(20.29%)	38	(34.23%)	12	(22.05%)	7.02 (2)	.240

251 To investigate whether there was a difference between those who completed the post-
 252 measure and those who did not, logistic regression was performed. The model found that the
 253 baseline characteristics of participants described in Table 1 did not predict whether participants
 254 completed the outcome measure battery [$\chi^2(11) = 9.79, p = .550$]. The model explained 0.5%
 255 in variance between the participants who completed the outcome measure and those who did
 256 not. The descriptive statistics are shown in Table 2.

257 At baseline the mean score for all participants on the PHQ-4 was 6.30 (*SD* = 2.74); 6.21%
 258 were classed as normal on this measure (*n* = 19), 35.29% were mild (*n* = 108), 33.66% were
 259 moderate (*n* = 103) and 24.84% were severe (*n* = 76). The mean score on the Mini SPIN
 260 was 5.69 (*SD* = 2.08). Characteristics of the participants by group are shown in Table 1 along
 261 with the results of the Kruskal–Wallis tests and Chi-squared comparisons between the groups.
 262 These found no significant differences between the groups.

263 *Effect of symptom monitoring on treatment receipt*

264 The proportion of participants who reported receiving treatment after starting the study was
 265 7.2% (10/138) in the control group, 8.1% (9/111) in the 6-day monitoring group and 15.8%
 266 (9/57) in the open monitoring group. Overall, 9.2% (28/306) of the participants started new
 267 treatment during the 30-day period.

268 Logistic regression found no significant difference between the proportion of people who
 269 reported receiving treatment in the control group and the 6-day monitoring group (OR = 1.13,

Table 2. Baseline characteristics of participants who completed the outcome measure and those that did not

Variable	Did not complete outcome measure (<i>n</i> = 6419)	Completed outcome measure (<i>n</i> = 306)
PHQ-4 score (<i>SD</i>)	6.43 (2.87)	6.30 (2.74)
Age (<i>SD</i>)	26.83 (9.26)	27.16 (9.69)
Female <i>n</i> (%)	4302 (67.0%)	217 (70.9%)
Ethnicity <i>n</i> (%)		
White	5344 (83.3%)	256 (83.7%)
Mixed	261 (4.1%)	7 (2.3%)
Asian	489 (7.6%)	29 (9.5%)
Black	159 (2.5%)	7 (2.3%)
Other or unknown	166 (2.6%)	7 (2.3%)
Intention to seek treatment (<i>SD</i>)	32.79 (31.96)	31.35 (31.20)
Belief in the effectiveness of psychotherapy (<i>SD</i>)	55.25 (28.27)	54.93 (27.03)
Belief in the effectiveness of medication (<i>SD</i>)	43.84 (28.19)	42.36 (27.38)
Received treatment before <i>n</i> (%)	1727 (26.9%)	78 (25.5%)

270 $p = .799$, 95% lower CI = 0.44, 95% upper CI = 2.88). However, there was a trend for people
 271 who were in the open monitoring group to be more likely to report receiving treatment than the
 272 control group (OR = 2.40, $p = .074$, 95% lower CI = 0.92, 95% upper CI = 6.27). Overall,
 273 this model was not found to be significantly better at predicting whether or not participants
 274 received treatment than a model that just contained the constant [$\chi^2(2) = 3.33$, $p = .189$] and
 275 only 2.4% of the variance in treatment receipt was explained, using Nagelkerke's R^2 .

276 *Post-hoc analysis on the role of intention to seek treatment*

277 As the previous analysis did not find a significant difference between groups, *post-hoc* analyses
 278 were undertaken to investigate whether intention to seek treatment had a moderating role
 279 between symptom monitoring and treatment receipt. In order to investigate whether the impact
 280 of symptom monitoring was greater among those who had high intention to seek treatment, a
 281 median split was used to differentiate between participants who had low *versus* high intention
 282 to seek treatment at baseline.

283 Among those with low intention to seek treatment, people in the 6-day and open monitoring
 284 groups were no more likely to report treatment receipt than the control group (OR = 0.65,
 285 $p = .628$, 95% lower CI = 0.12, upper CI = 3.69; and OR = 1.15, $p = .876$, 95% lower
 286 CI = 0.20, upper CI = 6.62, respectively). Overall, this model was not found to be significantly
 287 better at predicting whether or not participants received treatment than a model that just
 288 contained the constant [$\chi^2(2) = 0.35$, $p = .839$]. Nagelkerke's R^2 indicated that only 0.7% of
 289 the variance in treatment receipt was explained.

290 Among participants who stated that their intention to seek treatment was above or equal to
 291 the median score, people in the 6-day monitoring group were no more likely to report treatment
 292 receipt than the control group (OR = 1.41, $p = .564$, 95% lower CI = 0.44, upper CI = 4.46).

293 However, the open monitoring group was significantly more likely to report receiving treatment
294 than the control group (OR = 3.82, $p = .030$, 95% lower CI = 1.14, upper CI = 12.84). Overall,
295 this model was not found to be much better at predicting whether or not participants were more
296 likely to receive treatment than a model that just contains the constant, but a trend was found
297 [$\chi^2(2) = 4.78$, $p = .092$]. Nagelkerke's R^2 indicated that 5.8% of the variance in treatment
298 receipt was explained.

299 *Type of treatment sought*

300 Twenty-eight participants reported receiving treatment at the end of the study. For the majority
301 of these participants treatment was received from their general practitioner (75.0%, $n = 21$),
302 with one participant (3.6%) receiving treatment from an IAPT site and two (7.1%) receiving
303 treatment from a private therapist. Four participants (14.2%) did not state from whom they
304 received treatment.

305 Of the 28 participants who reported receiving treatment, 12 (42.9%) reported receiving a
306 psychological treatment, nine (32.1%) reported receiving medication, two (7.1%) reported
307 receiving both a psychological therapy and medication, and five (17.9%) reported an
308 unclassified type of treatment. Of those who received psychological therapies eight received
309 counselling (57.1%), five received CBT (35.7%) and one received psychodynamic therapy
310 (7.1%).

311 For the 28 participants who reported receiving treatment, four were diagnosed with
312 depression (14.2%), three with mixed anxiety and depression (10.7%), one with social phobia
313 (3.6%) and one with post-traumatic stress disorder (3.6%). However, the majority either did
314 not receive a diagnosis or stated they were not sure ($n = 15$, 53.5%). Two stated family loss
315 (7.1%) and one preferred not to disclose the diagnosis (3.6%).

316

Discussion

317 This study investigated the effect of monitoring symptoms on treatment receipt. The proportion
318 of participants who reported receiving treatment after starting the study was 7.2% (10/138)
319 in the information group, 8.1% (9/111) in the 6-day monitoring group and 15.8% (9/57) in
320 the open monitoring group. Half of the participants who reported receiving treatment received
321 psychological treatments, but it was unclear whether these were evidence based. Among those
322 that completed the final survey, participants who were able to monitor whenever they wished
323 were more likely to report receiving treatment than people who were only given information
324 about their local treatment services or were limited to using the app once every 6 days. The
325 impact of the intervention was greatest among participants who intended to seek treatment
326 before taking part in the study, consistent with the Transtheoretical Model of Change (Prochaska
327 and DiClemente, 1982).

328 This study indicates that monitoring symptoms for people with a high intention to seek
329 treatment might translate that intention into actual treatment-seeking behaviour, but if the
330 effect exists, it is small. Previous research indicates that most people with common mental
331 health disorders do not seek treatment, and those that do often wait a long time before
332 doing so (McManus et al., 2009; Wang et al., 2007). Delaying treatment can lead to negative
333 consequences for those with anxiety and depression (Brenes, 2007; Hawton and van Heeringen,
334 2009). Therefore, simple interventions to reduce the time it takes for people with anxiety and

335 depression to receive treatment are of potential value. The result of the current study leads some
336 support to the notion that interventions may be more effective if targeted at an individual's
337 current situation (Noar et al., 2007).

338 The majority of participants who received psychological treatments stated that they received
339 counselling. Counselling is one of the NICE-recommended treatments for depression (NICE,
340 2011), but it is not recommended by NICE for any other mental health disorder. As the majority
341 of participants did not report having received a diagnosis it is unclear whether the treatment
342 they were given was evidence based. Further work should focus on whether an intervention
343 can encourage people to receive treatments that are recommended by NICE, as opposed to
344 another type of psychological treatment.

345 This study was not the first to trial an intervention to increase the number of people seeking
346 or receiving treatment for anxiety and depression (Christensen et al., 2006). However, most
347 interventions that have previously attempted to increase treatment receipt have only increased
348 people's intention to seek treatment, rather than their behaviour (Gulliver et al., 2012). As
349 the aim of these interventions has been to change the antecedents to behaviour, the effects
350 on actual behaviour have frequently not been reported (Gulliver et al., 2012). The distinction
351 between intention and behaviour is important for future behaviour change research. In this
352 study, symptom monitoring was found to moderate the relationship between intention to seek
353 treatment and treatment receipt. Rather than trying to change the antecedents of behaviour,
354 interventions should also aim to increase the likelihood of intention being converted into
355 action and future behaviour change research should consider the relationship between these
356 two distinct constructs.

357 This study is subject to a number of limitations. Given the small number of people
358 who completed the post-measure, it might be possible that this study's findings cannot be
359 generalized to the wider population. Comparisons between the baseline characteristics of
360 the groups indicate that there were no observed systematic differences between those who
361 completed the post-measure and those who did not. It may also be the case that the effect
362 of the intervention on treatment receipt may be a statistical artefact – the absolute numbers
363 of people that reported receiving treatment were very similar. Analyses were undertaken to
364 test whether or not participants who completed the outcome measure differed significantly on
365 the measured variables by group. This was done to ascertain whether the differential drop-out
366 rates had biased the analyses. There were no systematic differences between the groups on the
367 measured variables, but this does not rule out the possibility of there being systematic biases
368 between the groups on unmeasured variables. It is interesting that approximately twice as
369 many participants completed the post-measure in the control and the 6-day monitoring group
370 compared with the open monitoring group. It may be the case that continually having access to
371 monitoring symptoms makes participants less inclined to complete post-measures. The high
372 drop-out rate in this study also led to the analyses being less powerful than predicted, given the
373 large initial sample size. High drop-out rates are common in eHealth trials – even up to 99.5%
374 (see Eysenbach, 2005) – and thus the rate observed in this trial is not considered anomalous.

375 The design of the application may have impacted the length of time it was used by people.
376 A number of authors have proposed certain design principles that have an impact on the length
377 of time a user engages with an application (Fogg and Eckles, 2007). However, these design
378 principles are rarely tested prospectively and robustly evaluated (Manzi, 2012). For this reason,
379 further robust evaluation of the design of applications in relation to their effects on behaviour
380 change should be undertaken.

381 This study did not collect information on suicidality in response to ethical concerns that if
 382 we were made aware of suicidality, we would be required to act. In order to act, we would have
 383 been required to identify individuals and monitor their responses. Given the nature of this study,
 384 it was not feasible to do so and we therefore omitted questions on suicidality for ethical reasons
 385 although such issues should be considered in future studies. Similarly it would be helpful for
 386 future studies to collect information on how often participants in the opening monitoring group
 387 monitored their symptoms and the monitoring behaviour of participants that did not complete
 388 the study. In addition, it is important to note that the timeframe of 30 days of monitoring was
 389 relatively arbitrary. It was chosen as it was considered that it would maximize engagement
 390 with the app and was sufficient to see fluctuations in mental health symptoms. However, it
 391 may have been too short to allow the full range of fluctuations to be captured and it was also
 392 inconsistent with the timeframe for the self-report measures of anxiety and depression which
 393 have a 2-week timeframe. Furthermore, the high drop-out rate would indicate a shorter period
 394 might be better for engagement and modifying the monitoring in some ways, for example
 395 personalizing messages and reminders, might also be beneficial for retention.

396 A further limitation is the study's dependency on the self-reported post-measures that are
 397 not diagnostic. As treatments were self-reported by the participants it is impossible to verify
 398 whether or not treatments actually took place. We specifically chose the wording of the question
 399 to reflect whether or not the participant reported receiving treatment instead of asking whether
 400 participants had sought treatment as we assumed there would be greater ambiguity about what
 401 behaviours can be considered as 'seeking' treatment. It is acknowledged that by wording the
 402 question in this way, participants who had sought treatment but were on a waiting list at time
 403 of study end would not be counted as having received treatment.

404 Future versions of this study could include the PHQ-9 and GAD-7 in the baseline and post-
 405 measure. This would allow us to establish whether symptom monitoring had an impact on
 406 participants' symptoms of anxiety or depression among participants who received treatment
 407 while using the application and those who did not. The work by Lambert and colleagues would
 408 suggest that participants who received psychotherapy and monitored their symptoms would
 409 have better outcomes than participants who received psychotherapy and do not monitor their
 410 symptoms (Kordy et al., 2001; Lambert, 2007, 2013; Lambert et al., 2003; Lutz et al., 2006).

411 The findings from this study indicate that symptom monitoring can encourage those who
 412 already have a high intention to seek treatment to actually seek it, provided that they are able
 413 to monitor their symptoms whenever they see fit. More generally, this study shows that cell
 414 phone applications can be used as a platform to run a randomized field trial, although high
 415 levels of drop-out are to be expected.

416

Acknowledgements

Q2 417 ~~Left blank for blind review.~~

Q3 418 *Ethical statements:* Ethical approval for this study was granted by ~~XXXXXX~~.

419 The authors assert that all procedures contributing to this work comply with the ethical
 420 standards of the relevant national and institutional committees on human experimentation and
 421 with the Helsinki Declaration of 1975, as revised in 2008.

422 *Conflicts of interest:* The authors have no conflicts of interest with respect to this publication.

Q4 423 *Financial support:* ~~Left blank for blind review.~~

424

References

- 425 **Ajzen, I.** (1991). The theory of planned behavior. *Organizational Behavior and Human Decision*
 426 *Processes*, 50, 179–211. doi: [10.1016/0749-5978\(91\)90020-T](https://doi.org/10.1016/0749-5978(91)90020-T)
- 427 **Brenes, G. A.** (2007). Anxiety, depression, and quality of life in primary care patients. *Primary Care*
 428 *Companion to the Journal of Clinical Psychiatry*, 9, 437–443.
- 429 **Christensen, H., Leach, L., Barney, L., Mackinnon, A. and Griffiths, K.** (2006). The effect of
 430 web based depression interventions on self reported help seeking: randomised controlled trial
 431 [ISRCTN77824516]. *BMC Psychiatry*, 6, 13. doi: [10.1186/1471-244X-6-13](https://doi.org/10.1186/1471-244X-6-13)
- 432 **Connor, K. M., Kobak, K. A., Churchill, L. E., Katzelnick, D. and Davidson, J. R.** (2001). Mini-
 433 SPIN: a brief screening assessment for generalized social anxiety disorder. *Depression and Anxiety*,
 434 14, 137–140. doi: [10.1002/da.1055](https://doi.org/10.1002/da.1055)
- 435 **Drake, G., Csipke, E. and Wykes, T.** (2012). Assessing your mood online: acceptability and use of
 436 Moodscope. *Psychological Medicine*, 1, 1–10. doi: [10.1017/S0033291712002280](https://doi.org/10.1017/S0033291712002280)
- 437 **Eysenbach, M.** (2005). The law of attrition. *Journal of Medical Internet Research*, 7. doi:
 438 [10.2196/jmir.7.1.e11](https://doi.org/10.2196/jmir.7.1.e11)
- 439 **Faul, F., Erdfelder, E., Lang, A.-G. and Buchner, A.** (2007). G*Power 3: a flexible statistical power
 440 analysis program for the social, behavioral, and biomedical sciences. *Behaviour Research Methods*
 441 *and Instruments*, 39, 175–191. doi: [10.3758/bf03193146](https://doi.org/10.3758/bf03193146)
- 442 **Fogg, B. and Eckles, D.** (eds) (2007). *Mobile Persuasion: 20 Perspectives on the Future of Behavior*
 443 *Change*. Stanford: Stanford Captology Media.
- 444 **Gulliver, A., Griffiths, K. M., Christensen, H. and Brewer, J. L.** (2012). A systematic review of help-
 445 seeking interventions for depression, anxiety and general psychological distress. *BMC Psychiatry*, 12,
 446 81. doi: [10.1186/1471-244X-12-81](https://doi.org/10.1186/1471-244X-12-81)
- 447 **Gulliver, A., Griffiths, K. M. and Christensen, H.** (2010). Perceived barriers and facilitators to mental
 448 health help-seeking in young people: a systematic review. *BMC Psychiatry*, 10, 113. doi: [10.1186/1471-244x-10-113](https://doi.org/10.1186/1471-244x-10-113)
- 449 **Hawton, K. and van Heeringen, K.** (2009). Suicide. *The Lancet*, 373, 1372–1381.
- 450 **Kessler, R. C. and Ustun, T.** (2008). *The WHO World Mental Health Surveys*. Cambridge University
 451 Press: Cambridge.
- 452 **Kordy, H., Hannöver, W. and Richard, M.** (2001). Computer-assisted feedback-driven quality
 453 management for psychotherapy: the Stuttgart-Heidelberg Model. *Journal of Consulting and Clinical*
 454 *Psychology*, 69, 173–183. doi: [10.1037//0022-006X.69.2.173](https://doi.org/10.1037//0022-006X.69.2.173)
- 455 **Kroenke, K., Spitzer, R. L. and Williams, J. B.** (2001). The PHQ-9: validity of a brief depression
 456 severity measure. *Journal of General Internal Medicine*, 16, 606–613. doi: [10.1046/j.1525-1497.2001.016009606.x](https://doi.org/10.1046/j.1525-1497.2001.016009606.x)
- 457 **Kroenke, K., Spitzer, R. L., Williams, J. B. W. and Löwe, B.** (2009). An ultra-brief screening scale
 458 for anxiety and depression: the PHQ-4. *Psychosomatics*, 50, 613–621. doi: [10.1176/appi.psy.50.6.613](https://doi.org/10.1176/appi.psy.50.6.613)
- 459 **Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O. and Löwe, B.** (2007). Anxiety
 460 disorders in primary care: prevalence, impairment, comorbidity, and detection. *Annals of Internal*
 461 *Medicine*, 146, 317–325. doi: [10.7326/0003-4819-146-5-200703060-00004](https://doi.org/10.7326/0003-4819-146-5-200703060-00004)
- 462 **Kwan, B. M., Dimidjian, S. and Rizvi, S. L.** (2010). Treatment preference, engagement, and clinical
 463 improvement in pharmacotherapy versus psychotherapy for depression. *Behaviour Research and*
 464 *Therapy*, 48, 799–804. doi: [10.1016/j.brat.2010.04.003](https://doi.org/10.1016/j.brat.2010.04.003)
- 465 **Lambert, M. J.** (2007). Presidential address: what we have learned from a decade of research aimed
 466 at improving psychotherapy outcome in routine care. *Psychotherapy Research*, 17, 1–14. doi:
 467 [10.1080/10503300601032506](https://doi.org/10.1080/10503300601032506)
- 468 **Lambert, M. J.** (2013). Outcome in psychotherapy: the past and important advances. *Psychotherapy*,
 469 50, 42–51. doi: [10.1037/a0030682](https://doi.org/10.1037/a0030682)

- 473 **Lambert, M. J., Whipple, J. L., Hawkins, E. J., Vermeersch, D. A., Nielsen, S. L. and Smart,**
474 **D. W.** (2003). Is it time for clinicians to routinely track patient outcome? A meta-analysis. *Clinical*
475 *Psychology: Science and Practice*, 10, 288–301. doi: [10.1093/clipsy.bpg025](https://doi.org/10.1093/clipsy.bpg025)
- 476 **Lemeshow, S. and Hosmer, D. W.** (1982). A review of goodness of fit statistics for use in the
477 development of Logistic regression models. *American Journal Epidemiology*, 115, 92–106. doi:
478 [10.1093/oxfordjournals.aje.a113284](https://doi.org/10.1093/oxfordjournals.aje.a113284)
- 479 **Löwe, B., Wahl, I., Rose, M., Spitzer, C., Glaesmer, H., Wingenfeld, K. et al.** (2010). A 4-item measure
480 of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-
481 4) in the general population. *Journal of Affective Disorders*, 122, 86–95. doi: [10.1016/j.jad.2009.](https://doi.org/10.1016/j.jad.2009.06.019)
482 [06.019](https://doi.org/10.1016/j.jad.2009.06.019)
- 483 **Lutz, W., Lambert, M. J., Harmon, S. C., Tschitsaz, A., Schürch, E. and Stulz, N.** (2006). The
484 probability of treatment success, failure and duration – what can be learned from empirical data to
485 support decision making in clinical practice? *Science*, 232, 223–232. doi: [10.1002/cpp.496](https://doi.org/10.1002/cpp.496)
- 486 **Manzi, J.** (2012). *Uncontrolled: The Surprising Payoff of Trial-and-Error for Business, Politics, and*
487 *Society*. New York, NY: Basic Books.
- 488 **McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A. and Otto, M. W.** (2013). Patient
489 preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic
490 review. *Journal of Clinical Psychiatry*, 74, 595–602. doi: [10.4088/JCP.12r07757](https://doi.org/10.4088/JCP.12r07757)
- 491 **McManus, S., Meltzer, H., Brugha, T., Bebbington, P. and Jenkins, R.** (eds). (2009). *Adult psychiatric*
492 *morbidity in England, 2007: results of a household survey*. Leeds: The NHS Information Centre for
493 Health and Social Care.
- 494 **National Institute for Health and Care Excellence (NICE)** (2011). *Common mental health disorders:*
495 *identification and pathways to care (CG123)*. Retrieved from: [http://www.nice.org.uk/nicemedia/live/](http://www.nice.org.uk/nicemedia/live/13476/54604/54604.pdf)
496 [13476/54604/54604.pdf](http://www.nice.org.uk/nicemedia/live/13476/54604/54604.pdf) (accessed 19 October 2013).
- 497 **Noar, S. M., Benac, C. N. and Harris, M. S.** (2007). Does tailoring matter? Meta-analytic review
498 of tailored print health behavior change interventions. *Psychological Bulletin*, 133, 673–693. doi:
499 [10.1037/0033-2909.133.4.673](https://doi.org/10.1037/0033-2909.133.4.673)
- 500 **NHS Choices Reporting Team** (2012). *Mental Health Content Report November 2012*. Retrieved from:
501 [http://www.nhs.uk/aboutNHSChoices/professionals/developments/Documents/Traffic%20reports/](http://www.nhs.uk/aboutNHSChoices/professionals/developments/Documents/Traffic%20reports/NHS%20Choices%20Mental%20Health%20Traffic%20-%20Nov%202012.pdf)
502 [NHS%20Choices%20Mental%20Health%20Traffic%20-%20Nov%202012.pdf](http://www.nhs.uk/aboutNHSChoices/professionals/developments/Documents/Traffic%20reports/NHS%20Choices%20Mental%20Health%20Traffic%20-%20Nov%202012.pdf) (accessed 26 July
503 2013).
- 504 **Prochaska, J. O. and DiClemente, C. C.** (1982). Transtheoretical therapy: toward a more integrative
505 model of change. *Psychotherapy: Theory, Research and Practice*, 19, 276–288. doi: [10.1037/h0088437](https://doi.org/10.1037/h0088437)
- 506 **Schomerus, G., Matschinger, H. and Angermeyer, M.** (2009). Attitudes that determine willingness
507 to seek psychiatric help for depression: a representative population survey applying the Theory of
508 Planned Behaviour. *Psychological Medicine*, 39, 1855–1865. doi: [10.1017/S0033291709005832](https://doi.org/10.1017/S0033291709005832)
- 509 **Seeley-Wait, E., Abbott, M. J. and Rapee, R. M.** (2009). Psychometric properties of the mini-social
510 phobia inventory. *Primary Care Companion to the Journal of Clinical Psychiatry*, 11, 231–236. doi:
511 [10.4088/PCC.07m00576](https://doi.org/10.4088/PCC.07m00576)
- 512 **Shafran, R., Clark, D. M., Fairburn, C. G., Arntz, A., Barlow, D. H., Ehlers, A. et al.** (2009). Mind
513 the gap: improving the dissemination of CBT. *Behaviour Research and Therapy*, 47, 902–909. doi:
514 [10.1016/j.brat.2009.07.003](https://doi.org/10.1016/j.brat.2009.07.003)
- 515 **Spitzer, R. L., Kroenke, K., Williams, J. B. W. and Löwe, B.** (2006). A brief measure for assessing
516 generalized anxiety disorder: the GAD-7. *Archives of Internal Medicine*, 166, 1092–1097. doi:
517 [10.1001/archinte.166.10.1092](https://doi.org/10.1001/archinte.166.10.1092)
- 518 **Tarrier, N., Liversidge, T. and Gregg, L.** (2006). The acceptability and preference for the psychological
519 treatment of PTSD. *Behaviour Research and Therapy*, 44, 1643–1656. doi: [10.1016/j.brat.2005.11.012](https://doi.org/10.1016/j.brat.2005.11.012)
- 520 **Wang, P. S., Angermeyer, M., Borges, G., Bruffaerts, R., Chiu, W. A., De Girolamo, G. et al.**
521 (2007). Delay and failure in treatment seeking after first onset of mental disorders in the World
522 Health Organization's World Mental Health Survey Initiative. *World Psychiatry*, 6, 177–185.

- 523 **Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B. and Kessler, R. C.** (2005). Twelve-
524 month use of mental health services in the United States: results from the National Comorbidity Survey
525 Replication. *Archives of General Psychiatry*, 62, 603–613. doi: [10.1001/archpsyc.62.6.629](https://doi.org/10.1001/archpsyc.62.6.629)
526 **Weeks, J. W., Spokas, M. E. and Heimberg, R. G.** (2007). Psychometric evaluation of the mini-social
527 phobia inventory (Mini-SPIN) in a treatment-seeking sample. *Depression and Anxiety*, 24, 382–391.
528 doi: [10.1002/da.20250](https://doi.org/10.1002/da.20250)